FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileAroa Biosurgery Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
ARX.AX
Aroa Biosurgery Limited Stock AnalysisComprehensive stock analysis for Aroa Biosurgery Limited (ARX.AX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisARX.AX
ARX.AX
Aroa Biosurgery Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
ARX.AX
  1. Home
  2. Stocks
  3. Aroa Biosurgery Limited

Aroa Biosurgery Limited

🇦🇺ARX.AX•ASX

Aroa Biosurgery Limited

🇦🇺ARX.AX•ASX
P/E ratio
42.08

Your view on ARX.AX

P/E
42.08
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Aroa Biosurgery Limited

Industry
Medical - Devices
Sector
Healthcare
CEO
Brian Ward
Headquarters
64 Richard Pearse Drive, Auckland, AU, NZ
Industry
Medical - Devices
Sector
Healthcare
CEO
Brian Ward
Headquarters
64 Richard Pearse Drive, Auckland, AU, NZ
Description

Aroa Biosurgery Limited operates as a regenerative medicine company dedicated to the development, production, and global distribution of medical solutions for wound and tissue repair. The firm innovatively utilizes extracellular matrix (ECM) technology, with its market presence spanning the United States and international territories.

Its product line encompasses Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold, tailored for managing both acute and chronic wounds.

Additionally, the company offers Myriad Matrix, an engineered ECM device designed for soft tissue repair, reinforcement, and complex wound treatment, along with Myriad Morcells, a powdered version of Myriad Matrix serving similar soft tissue and complex wound applications.

Rounding out its offerings are Reinforced Bioscaffolds, a specialized surgical product employed in ventral hernia repair and abdominal wall reconstruction. Founded in 2007, Aroa Biosurgery Limited is headquartered in Auckland, New Zealand.

Financial Data

Stock Data

Price chart, volume, and trading data.

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for Aroa Biosurgery Limited from FRC's valuation model, read against the market price. ARX.AX last traded at AUD 0.56, 42.1× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Aroa Biosurgery Limited. Starting points for Aroa Biosurgery Limited: P/E 42.1, EPS AUD 0.01, beta 0.85 — an Medical - Devices name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Aroa Biosurgery Limited. Aroa Biosurgery Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Aroa Biosurgery Limited. Trailing twelve-month EPS for Aroa Biosurgery Limited stands at AUD 0.01. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 20, 2026 · AUD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Earnings Estimate

EPSCurrent QtrJun 2026Next QtrSep 2026Current YearFY Mar 2027Next YearFY Mar 2028
Avg. estimateAUD 0.00AUD 0.00AUD 0.01AUD 0.03
Low estimateAUD 0.00AUD 0.00AUD 0.01AUD 0.02
High estimateAUD 0.00AUD 0.00AUD 0.02AUD 0.04
No. of analysts0133
Year-ago EPSAUD 0.011−AUD 0.001AUD 0.011—
Growth————

1Year-ago EPS includes one-time items; growth not shown.

Revenue Estimate

RevenueCurrent QtrJun 2026Next QtrSep 2026Current YearFY Mar 2027Next YearFY Mar 2028
Avg. estimateAUD 53.98MAUD 45.34MAUD 98.31MAUD 112.80M
Low estimateAUD 53.98MAUD 45.34MAUD 96.79MAUD 108.29M
High estimateAUD 53.98MAUD 45.34MAUD 99.89MAUD 116.52M
No. of analysts1133
Year-ago revenueAUD 20.69MAUD 41.08MAUD 92.28M—
Growth+160.8%+10.4%+6.5%—

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 20, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Aroa Biosurgery Limited. Aroa Biosurgery Limited has reported as a listed company since 2020. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold ARX.AX18 companies
Compare ARX.AX with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustry
CMB.AXCambium Bio LimitedHealthcareBiotechnology—
OCC.AXOrthocell LimitedHealthcareBiotechnology—
OSX.AXOsteopore LimitedHealthcareMedical - Instruments & Supplies—
PNV.AXPolyNovo LimitedHealthcareMedical - Devices—
TRP.AXTissue Repair LtdHealthcareBiotechnology—
TTX.AXTetratherix Ltd.HealthcareBiotechnology—
More Medical - Devices companies
TickerTypeCompanySectorExchangeMkt cap
CBLLCeriBell, Inc.HealthcareNASDAQ$995.3M
CERSCerus CorporationHealthcareNASDAQ$391.8M
CGHCCapital Group Holdings, Inc.HealthcareOTC$9,220
CHEOFCochlear LimitedHealthcareOTC$8.9B
CHEOYCochlear LimitedHealthcareOTC$9.2B
CHYPFHealth Logic Interactive Inc.HealthcareOTC$165,839
CLLKFBICO Group AB (publ)HealthcareOTC$123.3M
CLPTClearPoint Neuro, Inc.HealthcareNASDAQ$247.1M
CLVSFCellaVision AB (publ)HealthcareOTC$378.0M
CMP.AXCompumedics LimitedHealthcareASX—
CNMDCONMED CorporationHealthcareNYSE$1.4B
CNVIFConavi Medical Corp.HealthcareOTC$20.7M
Open Comparable Analysis
Ownership & News

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Aroa Biosurgery Limited. Coverage tracks Aroa Biosurgery Limited within Medical - Devices (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Aroa Biosurgery Limited.

ARX.AX AnalysisFair
Past
1
Growth
5
Health
5
Profit
2
Value
1

News

Latest Market News